Multicenter, Prospective, Double-Blinded, Parallel Group, Randomized Phase III Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Latest Information Update: 08 Jun 2025
At a glance
- Drugs Immune globulin (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Registrational; Therapeutic Use
- Sponsors Octapharma
Most Recent Events
- 03 Oct 2023 Status changed from not yet recruiting to recruiting.
- 02 Oct 2023 Planned initiation date changed from 1 Jul 2023 to 1 Nov 2023.
- 03 Jul 2023 Planned primary completion date changed from 1 Dec 2025 to 1 Jun 2026.